Doxofylline 69975-86-6
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
266.25 Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.
Biological Activity
Doxofylline has PDE Inhibitor activity and can increase the level of
cAMP, which could, therefore, be used for the treatment of asthma and
COPD. EC50 value of Doxofylline is 15 times higher than that of
aminophylline in inhibiting the adenosine-induced relaxation of
tracheal smooth muscle and 10 times higher in reducing the negative
inotropic effect induced by adenosine on isolated guinea-pig atria.
Doxofylline could effectively decrease the open probability of the
calcium-activated potassium channels as a result of both the shortening
of open period and the prolongation of close time. Doxofylline has
greatly decreased affinity towards adenosine A1 and A2 receptors when
compared with theophylline, which may contribute to the better safety
profile. Moreover, unlike theophylline, Doxofylline does not interfere
with calcium influx into cells nor antagonizes the action of
calcium-channel blockers.
Doxofylline has been shown to have better efficacy with fewer side
effects than theophylline. 30 mg/kg Doxofylline increases heart rate of
anaesthetized cat by 13 beats/min. The effective therapeutic dose of
Doxofylline has less cardio-stimulant effects than Theophylline, such
that Doxofylline does not out significantly increase the cardiac
frequency nor does it have arrhythmogenic effects.
Contact us if you need more details on 69975-86-6. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Doxofylline 69975-86-6、69975-86-6 Doxofylline. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
266.25 Doxofylline is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.
Biological Activity
Doxofylline has PDE Inhibitor activity and can increase the level of
cAMP, which could, therefore, be used for the treatment of asthma and
COPD. EC50 value of Doxofylline is 15 times higher than that of
aminophylline in inhibiting the adenosine-induced relaxation of
tracheal smooth muscle and 10 times higher in reducing the negative
inotropic effect induced by adenosine on isolated guinea-pig atria.
Doxofylline could effectively decrease the open probability of the
calcium-activated potassium channels as a result of both the shortening
of open period and the prolongation of close time. Doxofylline has
greatly decreased affinity towards adenosine A1 and A2 receptors when
compared with theophylline, which may contribute to the better safety
profile. Moreover, unlike theophylline, Doxofylline does not interfere
with calcium influx into cells nor antagonizes the action of
calcium-channel blockers.
Doxofylline has been shown to have better efficacy with fewer side
effects than theophylline. 30 mg/kg Doxofylline increases heart rate of
anaesthetized cat by 13 beats/min. The effective therapeutic dose of
Doxofylline has less cardio-stimulant effects than Theophylline, such
that Doxofylline does not out significantly increase the cardiac
frequency nor does it have arrhythmogenic effects.
Contact us if you need more details on 69975-86-6. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Doxofylline 69975-86-6、69975-86-6 Doxofylline. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Metabolism > PDE Inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9